REG - Nuformix PLC - Publication of a Prospectus

NuformixAnnouncement

Yesterday 13:15

For best results when printing this announcement, please click on link below:
https://newsfile.refinitiv.com/getnewsfile/v1/story?guid=urn:newsml:reuters.com:20250523:nRSW0231Ka&default-theme=true

RNS Number : 0231K  Nuformix PLC  23 May 2025

THIS ANNOUNCEMENT AND THE INFORMATION IN IT, IS RESTRICTED AND IS NOT FOR
PUBLICATION, RELEASE OR DISTRIBUTION, DIRECTLY OR INDIRECTLY, IN WHOLE OR IN
PART, IN OR INTO THE UNITED STATES, AUSTRALIA, CANADA, THE REPUBLIC OF SOUTH
AFRICA, JAPAN, NEW ZEALAND, SINGAPORE OR ANY OTHER JURISDICTION IN WHICH SUCH
PUBLICATION, RELEASE OR DISTRIBUTION WOULD BE UNLAWFUL.

 

THIS ANNOUNCEMENT IS AN ADVERTISEMENT FOR THE PURPOSES OF THE PROSPECTUS
REGULATION RULES OF THE UK FINANCIAL CONDUCT AUTHORITY ("FCA") AND IS NOT A
PROSPECTUS. THIS ANNOUNCEMENT DOES NOT CONSTITUTE OR FORM PART OF, AND SHOULD
NOT BE CONSTRUED AS, AN OFFER FOR SALE OR SUBSCRIPTION OF, OR SOLICITATION OF
ANY OFFER TO SUBSCRIBE FOR OR TO ACQUIRE, ANY ORDINARY SHARES IN NUFORMIX PLC
IN ANY JURISDICTION, INCLUDING IN OR INTO THE UNITED STATES, CANADA,
AUSTRALIA, THE REPUBLIC OF SOUTH AFRICA OR JAPAN. INVESTORS SHOULD NOT
SUBSCRIBE FOR OR PURCHASE ANY ORDINARY SHARES REFERRED TO IN THIS ANNOUNCEMENT
EXCEPT ON THE BASIS OF INFORMATION IN THE PROSPECTUS (THE "PROSPECTUS") IN ITS
FINAL FORM, PUBLISHED BY NUFORMIX PLC IN CONNECTION WITH THE PROPOSED
ADMISSION OF THE NEW ORDINARY SHARES TO THE EQUITY SHARES (TRANSITION)
CATEGORY OF LONDON STOCK EXCHANGE PLC'S MAIN MARKET FOR LISTED SECURITIES.

 

THIS ANNOUNCEMENT CONTAINS INSIDE INFORMATION FOR THE PURPOSES OF ARTICLE 7 OF
EU REGULATION 596/2014 (WHICH FORMS PART OF DOMESTIC UK LAW PURSUANT TO THE
EUROPEAN UNION (WITHDRAWAL) ACT 2018 ("EUWA")) ("UK MAR").

 

23 May 2025

 

Nuformix plc

 

("Nuformix" or the "Company")

 

Publication of Prospectus

 

Nuformix plc (LSE:NFX), a pharmaceutical development company targeting unmet
medical needs in fibrosis and oncology via drug repurposing, announces that,
further to the conditional £210,000 placing announced on 22 May 2025 (the
"Placing"), the Company has today published a prospectus (the "Prospectus")
relating to the proposed issuance of 300,000,000 new ordinary shares ("New
Ordinary Shares") at a price of 0.07 pence per share (the "Issue Price").

 

The Placing and issue of the New Ordinary Shares remains subject to the
fulfilment of the following conditions ("Conditions"): (i) there being no
breach of the obligations under the placing agreement entered into between CMC
Markets UK Plc ("CMC Markets") and the Company prior to Admission; and (ii)
admission of the New Ordinary Shares to trading on the Main Market of the
London Stock Exchange ("Admission") becoming effective.

 

An electronic copy of the Prospectus and the Notice of General Meeting are
available for inspection on the Company's website at:
https://nuformix.com/document-center/ (https://nuformix.com/document-center/)

 

The Prospectus will also be available for inspection at the National Storage
Mechanism at: https://data.fca.org.uk/#/nsm/nationalstoragemechanism
(https://data.fca.org.uk/#/nsm/nationalstoragemechanism) .

 

Admission and Total Voting Rights

 

Application will be made to the London Stock Exchange for the New Ordinary
Shares to be admitted to the equity shares (transition) category the Financial
Conduct Authority's Official List and to trading on the Main Market of the
London Stock Exchange, assuming the Conditions are met ("Admission").  It is
expected that Admission and unconditional dealings in the New Ordinary Shares
will commence on the London Stock Exchange at 8.00 a.m. on 30 May 2025.

 

Following Admission of the New Ordinary Shares, the total number of Ordinary
Shares in issue will be 1,995,709,368, each with one voting right.  The
Company does not hold any rights in treasury.  The total voting rights figure
is therefore 1,995,709,368 and can be used by shareholders as the denominator
for the calculations by which they will determine whether they are required to
notify their interest in, or a change of their interest in, the Company under
the Disclosure Guidance and Transparency Rules of the Financial Conduct
Authority.

 

Enquiries:

 

 Nuformix plc
 Dr Dan Gooding, Executive Director  Via IFC Advisory

 CMC Markets
 Douglas Crippen                     +44 (0) 20 3003 8632

 IFC Advisory Limited
 Tim Metcalfe                        +44 (0) 20 3934 6630

 Zach Cohen                          nuformix@investor-focus.co.uk

 

About Nuformix

 

Nuformix is a pharmaceutical development company targeting unmet medical needs
in fibrosis and oncology via drug repurposing. The Company aims to use its
expertise in discovering, developing and patenting novel drug forms, with
improved physical properties, to develop new products in new indications that
are, importantly, differentiated from the original (by way of dosage, delivery
route or presentation), thus creating new and attractive commercial
opportunities. Nuformix has a pipeline of preclinical assets with potential
for significant value and early licensing opportunities.

 

This information is provided by RNS, the news service of the London Stock Exchange. RNS is approved by the Financial Conduct Authority to act as a Primary Information Provider in the United Kingdom. Terms and conditions relating to the use and distribution of this information may apply. For further information, please contact
rns@lseg.com (mailto:rns@lseg.com)
 or visit
www.rns.com (http://www.rns.com/)
.

RNS may use your IP address to confirm compliance with the terms and conditions, to analyse how you engage with the information contained in this communication, and to share such analysis on an anonymised basis with others as part of our commercial services. For further information about how RNS and the London Stock Exchange use the personal data you provide us, please see our
Privacy Policy (https://www.lseg.com/privacy-and-cookie-policy)
.   END  PDIEAASDAEASEFA